| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Mogroside V targets metabolic and inflammatory pathways. It has an in vitro AMPK activating effect. It reduces intracellular reactive oxygen species (ROS) levels and enhances mitochondrial function. It also has anti-inflammatory potential in murine macrophages and a murine ear edema model, and protects against LPS-induced airway inflammation in a model of ALI.
|
|---|---|
| ln Vitro |
In vitro, mogroside V (20 μM, 40 hours) lowers the levels of ROS in mature oocytes [1]. Mogroside V (20 μM, 40 hours) can improve the mitochondrial culture function of oocytes [1]. By modifying STAT3 signaling, mogroside V (1) -250 μM, 24 hours) stimulates pancreatic islet and cell cycle arrest in the pancreas (PANC-1) [3]. fluorescent imaging [1]
In vitro, Mogroside V demonstrates significant biological activity. It activates AMPK. It reduces intracellular ROS levels and enhances mitochondrial function. It also shows anti-inflammatory potential in murine macrophages. Its antioxidant, anti-diabetic, and anti-carcinogenic effects have been well-documented. |
| ln Vivo |
In two diabetes models, the oral drug mogroside V (100 mg/kg) undergoes conversion into 26 metabolites via the processes of dehydrogenation, deoxygenation, oxidation, and carbonation [1].
In vivo, Mogroside V has shown efficacy in preclinical models. It has anti-inflammatory potential in a murine ear edema model. It protects against LPS-induced airway inflammation in a model of acute lung injury (ALI). It also possesses tumor growth inhibitory activity in pancreatic cancer models. Its antioxidant and antidiabetic effects are believed to contribute to its health benefits. |
| Enzyme Assay |
The in vitro AMPK activation assay for Mogroside V involves treating cells with the compound and measuring the phosphorylation of AMPK and its downstream target ACC by Western blotting. For antioxidant activity, its ability to scavenge free radicals (DPPH, ABTS) or reduce ROS levels in cells can be measured. Anti-inflammatory activity is assessed by measuring cytokine production in LPS-stimulated macrophages.
|
| Cell Assay |
Immunofluorescence[1]
Cell Types: IVM o Members Tested Concentrations: 20 μM Incubation Duration: 40 hrs (hours) Experimental Results: Compared with the control group, the fluorescence intensity increased. The red/green fluorescence intensity ratio increased compared to the control group. Real-time qPCR[1] Cell Types: IVM Oocyte Tested Concentrations: 20 μM Incubation Duration: 40 h Experimental Results: The relative expression of SOD, CAT, PGC-1α and TFAM mRNA increased compared with the control group. Cell viability assay[3] Cell Types: PANC-1 Cell Tested Concentrations: 1-250 μM Incubation Duration: 24 hrs (hours) Experimental Results: The percentage of TUNEL-positive cells increased from 2.91% to 92.25%. Apoptosis analysis [3] Cell Types: PANC-1 Cell Tested Concentrations: 1-250 μM Incubation Duration: 24 hrs (hours) Experimental Results: Induction of PANC-1 cell apoptosis in a concentration- and time-dependent manner Western Blot analysis [3] Cell Types: PANC-1 Cell Tested Concentrations: 0-250 μM Incubation Duration: 24 hrs (hours) Experimental Results: Expression of cyclin kinase inhibitors CDKN1A (p21WAF1) and CDKN1B (p27) incre In vitro cell culture studies for Mogroside V utilize various cell lines. Its anti-inflammatory effects are studied in murine macrophages. Its anticancer activity is assessed in cancer cell lines, such as pancreatic cancer cells, using MTT assays. Its effect on glucose metabolism and mitochondrial function is studied in skeletal muscle, liver, or pancreatic β-cells. |
| Animal Protocol |
Animal/Disease Models: T2D model rat [2] ]
Doses: 100 mg/kg Route of Administration: po (oral gavage) Experimental Results: Compared with blank biological samples, 28 mogroside V metabolites were detected. Metabolite peak areas in plasma samples from T2D rats were larger than those in healthy samples. In vivo animal experiments for Mogroside V have been performed in several models. Its anti-inflammatory effects have been studied in a murine ear edema model. Its protective effects against airway inflammation have been studied in a model of ALI. Its antitumor efficacy has been evaluated in pancreatic cancer xenograft models. |
| ADME/Pharmacokinetics |
Mogroside V has a molecular formula of C60H102O29 and a molecular weight of 1287.43 g/mol. It is a solid compound that is soluble in water and organic solvents like DMSO. As a glycoside, it is highly polar. It is typically stored as a powder at -20°C for long-term stability. Its stability is maintained under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
Toxicological data for Mogroside V indicate that it is safe for human consumption as a sweetener. It is generally recognized as safe (GRAS) for use in food. As a research compound, it is well-tolerated, and comprehensive toxicity studies have not shown significant adverse effects at dietary levels. However, high doses may have laxative effects.
|
| References |
|
| Additional Infomation |
Mogroside V is a β-D-glucoside and also a mogroside. It is a plant metabolite functionally related to Siraitia mogroside I. Mogroside V has been reported to exist in Siraitia siamensis and Siraitia grosvenorii, and relevant data are available.
Mogroside V is widely used as a low-calorie sweetener in food and beverages and is approved as a food additive in many countries. It is also a research compound with no clinical approval as a drug. Its AMPK activating, antioxidant, and anti-inflammatory properties make it a compound of interest for research into diabetes, obesity, inflammation, and cancer. |
| Molecular Formula |
C60H102O29
|
|---|---|
| Molecular Weight |
1287.43
|
| Exact Mass |
1286.65
|
| CAS # |
88901-36-4
|
| PubChem CID |
24721270
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.644
|
| LogP |
-1.07
|
| Hydrogen Bond Donor Count |
19
|
| Hydrogen Bond Acceptor Count |
29
|
| Rotatable Bond Count |
20
|
| Heavy Atom Count |
89
|
| Complexity |
2360
|
| Defined Atom Stereocenter Count |
35
|
| SMILES |
C[C@H](CC[C@H](C(C)(C)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)[C@H]4CC[C@@]5([C@@]4(C[C@H]([C@@]6([C@H]5CC=C7[C@H]6CC[C@@H](C7(C)C)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O)O)C)O)C)C
|
| InChi Key |
GHBNZZJYBXQAHG-KUVSNLSMSA-N
|
| InChi Code |
InChI=1S/C60H102O29/c1-23(9-13-35(57(4,5)79)88-55-50(89-54-49(78)43(72)38(67)29(20-63)84-54)45(74)40(69)31(86-55)22-81-52-47(76)42(71)37(66)28(19-62)83-52)24-15-16-58(6)32-12-10-25-26(60(32,8)33(64)17-59(24,58)7)11-14-34(56(25,2)3)87-53-48(77)44(73)39(68)30(85-53)21-80-51-46(75)41(70)36(65)27(18-61)82-51/h10,23-24,26-55,61-79H,9,11-22H2,1-8H3/t23-,24-,26-,27-,28-,29-,30-,31-,32+,33-,34+,35-,36-,37-,38-,39-,40-,41+,42+,43+,44+,45+,46-,47-,48-,49-,50-,51-,52-,53+,54+,55+,58+,59-,60+/m1/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[[(2R,3S,4S,5R,6R)-6-[[(3S,8S,9R,10R,11R,13R,14S,17R)-17-[(2R,5R)-5-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-hydroxy-6-methylheptan-2-yl]-11-hydroxy-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~77.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (1.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (1.62 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (1.62 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7767 mL | 3.8837 mL | 7.7674 mL | |
| 5 mM | 0.1553 mL | 0.7767 mL | 1.5535 mL | |
| 10 mM | 0.0777 mL | 0.3884 mL | 0.7767 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
